Umbilical Cord Blood Harvesting and Storage for Future Use (for Tennessee Only)
Customize your policy alerts
Sign up for UnitedHealthcare Policy CS127TN.P alerts
Get alerted when Policy CS127TN.P changes without checking for updates manually.
Monitor payer policy activity
Policy governing Medicaid and CoverKids in Tennessee on prophylactic/private collection and cryogenic storage of umbilical cord blood for potential future autologous or allogeneic use.
Added reference link to the Optum Clinical Guideline titled Hematopoietic Stem Cell Transplantation.
Updated FDA and References sections to reflect the most current information.
Archived previous policy version CS127TN.O.
Coverage Criteria for Umbilical Cord Blood Collection and Storage
Not covered for prophylactic/private banking
Covered stance and conditions
Due to insufficient evidence of efficacy; see specialty society guidance (AAP, ACOG, ASTCT).
Recommended directed banking / public donation
Exceptions and preferential practices per specialty societies
ASTCT/ACOG recommend directed banking for known at-risk families; AMA and ACOG encourage public donation when available.
Supported by ASTCT, AMA, ACOG, and RCOG guidance.
Routine collection and cryogenic storage of umbilical cord blood for otherwise healthy, low-risk families is not supported and is excluded from medical necessity coverage. The policy states that, due to insufficient evidence of efficacy, prophylactic collection and storage intended to preserve the opportunity for an unspecified future autologous or allogeneic transplant is considered unproven and not medically necessary for a currently healthy individual.
The rationale for excluding prophylactic/private cord blood banking is the lack of high-quality evidence demonstrating clinical benefit for otherwise healthy individuals. Specialty guidance from the American College of Obstetricians and Gynecologists (ACOG) emphasizes that the likelihood an autologous cord blood unit will be used by the child or family is remote unless there is a known family member with a condition treatable by transplant. ACOG therefore does not support routine private banking and recommends that families be informed about the low probability of future use and the financial obligations of private banks.
When a family member (for example, a full sibling) is known to have a disorder potentially treatable with allogeneic transplant, specialty societies recommend directed family banking as a preferred approach; otherwise, public donation is encouraged when available to provide broader societal benefit.
| Regimen / Indication | Coverage status | Notes |
|---|---|---|
| Cord blood transplantation — use of cord blood as a source of hematopoietic (blood-forming) stem cells for transplant (e.g., treatment of leukemia, lymphoma, myeloma, aplastic anemia, certain immunologic and metabolic disorders) | ||
| Informational | ||
| Public banking is encouraged; storage for personal use is not recommended except for directed family banking when there is a known affected sibling or family member who may benefit from an allogeneic transplant. For additional guidance, see the Optum Clinical Guideline: Hematopoietic Stem Cell Transplantation. |
Procedure and Billing Codes
| 38205 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic. |
| 38206 | Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous. |
| 38207 | Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage. |
| 88240 | Cryopreservation, freezing and storage of cells, each cell line |
| S2140 | Cord blood harvesting for transplantation, allogeneic |
Provider Actions, Prior Authorization, and Billing Guidance
Prior authorization expectation for prophylactic/private cord blood banking
Prophylactic/private cord blood collection and storage for an otherwise healthy individual is considered unproven and not medically necessary; prior authorization is unlikely to be approved absent documentation of a sibling or family member with a condition treatable by allogeneic transplant. Providers should obtain prior authorization when billing for harvesting or storage procedures but expect denials when the request is for routine prophylactic/private banking for a healthy newborn.
- Prior authorization required if submitting claims for cord blood harvesting or storage codes (see coding block).
- Provide documentation of a known affected sibling or family member with an indication for allogeneic transplant to support approval.
Prefer directed family banking when a known affected sibling exists
Specialty society guidance recommends directed (family) banking when there is a known sibling with a disease that may be successfully treated with an allogeneic transplant; public banking is encouraged when available. Providers should recommend directed family banking over routine private banking when an affected sibling is known.
- Encourage directed family banking when a full sibling has a condition treatable with cord blood transplant.
- Inform families about public donation as the preferred option when available.
Coding and documentation requirements when billing for harvesting or storage
If billed, use the applicable harvesting and storage procedure codes and ensure documentation supports medical necessity per policy. Document clinical rationale, family history, and any evidence of an affected sibling or qualifying family member; include consent and notice of financial obligations when using private banks.
- Use codes such as 38205, 38206, 38207, 88240, and S2140 when applicable.
- Include documentation of medical necessity (e.g., identified affected sibling), informed consent, and counseling about public vs private banking.
- Retain records of counseling on likelihood of autologous use and any fees/financial obligations disclosed to the family.
Denial risk for prophylactic/private cord blood banking
Requests for routine prophylactic/private cord blood collection and storage for a healthy newborn are subject to denial as not medically necessary. Claims for harvesting or storage billed without documentation of a qualifying affected family member are at high risk of denial.
- Denial risk is high for routine prophylactic/private banking due to insufficient evidence of efficacy.
- Provide documentation of a known affected sibling or family member to mitigate denial risk.
Definitions
Background
Umbilical cord and placental blood are sources of hematopoietic stem cells that can be used to treat hematologic malignancies, marrow failure, and certain immunologic and metabolic disorders. Cord blood banking captures and cryopreserves these cells at birth so they may be available for future autologous or allogeneic hematopoietic stem cell transplantation.
There are two common approaches to cord blood banking: public donation, in which units are made available to any matching recipient, and private (directed) banking, in which units are stored by a for-profit bank for potential future use by the child or family. Specialty guidance favors public donation for societal benefit and recommends directed banking when there is a known affected family member who may benefit from a transplant.
Revision History and Policy Changes
Added related-policy cross-reference to the Optum Clinical Guideline 'Hematopoietic Stem Cell Transplantation'; updated FDA and References sections; archived previous policy version CS127TN.O.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.